Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393452 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
A Phase 2 study of Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 8
- Study locations
NCT06393452 is a Phase 2 study of Androgenetic Alopecia that has completed, run by Pelage Pharmaceuticals. The registered enrollment target is 78 participants, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (51% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT06393452, a Phase 2 study of Androgenetic Alopecia, has completed, sponsored by Pelage Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.
Conditions Studied
Interventions
- DRUG PP405 0.05% Topical Gel
- DRUG PP405 Topical Vehicle Gel
Study Locations (8)
California
- California Dermatology & Clinical Research Institute - Encinitas
- Clinical Trials Research Institute - Thousand Oaks
Texas
- DermResearch - Austin
- Stride Clinical Research LLC - Sugar Land
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Minnesota
- Minnesota Clinical Study Center - New Brighton
Utah
- Jordan Valley Dermatology Center - South Jordan
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393452
The ClinicalTrials.gov registry entry for NCT06393452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (51% lower). The listed sponsor is Pelage Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 2 interventions - of which PP405 0.05% Topical Gel is the first listed.
NCT06393452 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT06393452 about?
NCT06393452 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA". The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration wit...
What is the current status of trial NCT06393452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-06-05. Estimated completion is 2025-10-01.
What conditions does trial NCT06393452 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT06393452?
The interventions under investigation include: PP405 0.05% Topical Gel (DRUG), PP405 Topical Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT06393452?
This trial is sponsored by Pelage Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393452 being conducted?
This trial has 8 study locations across California, Indiana, Minnesota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 2
-
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
COMPLETED · Phase 2
-
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
COMPLETED · Phase 2
-
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.